The Filing Desk

Fulgent Genetics vs Viemed Healthcare

Fulgent Genetics FLGT · Viemed Healthcare VMD · Health Care Services

Fulgent Genetics reported revenue of $323 million in fiscal 2025, 1.2 times Viemed Healthcare's $270 million in fiscal 2025. Fulgent Genetics' revenue grew 13.8% in its latest year, and Viemed Healthcare's grew 20.5%. Fulgent Genetics had an operating margin of -28.2%, against 8.5% at Viemed Healthcare. Free cash flow was −$124 million at Fulgent Genetics and $12 million at Viemed Healthcare.

Side by side

Fulgent GeneticsViemed Healthcare
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$323M$270M
Revenue growth13.8%20.5%
Revenue growth a year, last 5 years−5.2%15.5%
Gross margin40.6%57.5%
Operating margin−28.2%8.5%
Net margin−18.8%5.5%
Free cash flow−$124M$12M
Free cash flow margin−38.5%4.4%
Return on capital−8.7%12.4%
Net debt to EBITDA—−0.0x
Dividends and buybacks$11M$13M
Change in diluted share count1.8%0.1%
Last close$24.78$8.61
P/E at the last close—22.7×
Insider trades, last 12 monthssold $386,628sold $1.6 million
Piotroski F-score4 of 95 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Fulgent GeneticsViemed Healthcare
Operating margin
Percent of revenue
Fulgent GeneticsViemed Healthcare
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Fulgent GeneticsViemed Healthcare

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Fulgent Genetics and Viemed Healthcare pages.